Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
Cannabis Law Report
SEPTEMBER 20, 2021
(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Christopher M. Betsy Brod.
Let's personalize your content